Regulation of Immunological Cytokines by Qiliqiangxin Capsule in Dilated Cardiomyopathy Patients
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Purpose :Research into the impact of Qiliqiangxin capsule on IFN-γ，IL-4，NT-proBNP in dilated
cardiomyopathy patients with heart failure.
Methods :Data were collected from the patients with idiopathic dilated cardiomyopathy (
cardiac function NYHA Ⅱ-Ⅳ) in the first affiliated hospital of Harbin Medical University from
May 2012 to April 2014. These 30 cases were treated under the recommendations of normal
diagnosis and treatment in cardiomyopathy. This experiment was randomized double-blinded，the
experimental interferences were avoided and patients were divided into the experimental group
and the placebo group. The patients in experimental group received the relevant tests and
inspections before the beginning of experiment，signed the informed consent. Then the
investigators get the venous blood centrifugalization and cryopreservation. The patients take
the medicine qiliqiangxin three times per day，four tablets at a time. Afrer a month，the
investigators evaluated the symptoms，the function of heart，blood pressure，heart rate and keep
blood specimens. Three and six month later，electrocardiogram and echocardiography were taken
and the determination of the NT - proBNP was done. The placebo group was followed up in the
same way.